The Role of the LY294002 - A Non-Selective Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) Pathway- in Cell Survival and Proliferation in Cell Line SCC-25.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 Nov 2019
Historique:
received: 26 02 2019
entrez: 25 11 2019
pubmed: 25 11 2019
medline: 9 4 2020
Statut: epublish

Résumé

The activation of PI3K further activates subsequent regulatory pathways, which are activated via AKT phosphorylation. AKT is closely related to the Bcl-2 family, a protein known to be involved in cell survival. AKT also has a relationship with inflammatory and glycolytic mediators. The present work aimed to evaluate the relationship between the PI3K/AKT pathway, cell survival/proliferation, inflammatory mediators and the glycolytic pathway in oral squamous cell carcinoma. All experiments were performed in the SCC25 oral squamous cell carcinoma cell line. In the presence or absence of PI3K pathway inhibitors, we analyzed the protein expression of pAKT and AKT; X-linked inhibitor of apoptosis protein; Bcl-2-associated death promoter; Bcl-2-like protein two inhibitor; cyclooxygenase 1; cyclooxygenase-2; and glycoprotein-associated glucose transporter 1. For the functional characterization of treated or untreated cells, we also performed matrix invasion assays, cell migration assays, and cell proliferation assays. Our results demonstrated that activation of the PI3K/AKT pathway is directly related to members of the Bcl-2 family and GLUT1, but not the inflammatory mediators COX1 and COX2. Our data suggest that the PI3K/AKT pathway is related to cell survival and proliferation in oral squamous cell carcinoma through its interaction with Bcl-2 family members.<br />.

Identifiants

pubmed: 31759362
doi: 10.31557/APJCP.2019.20.11.3377
pmc: PMC7063005
pii:
doi:

Substances chimiques

Chromones 0
Enzyme Inhibitors 0
Morpholines 0
Phosphoinositide-3 Kinase Inhibitors 0
Proto-Oncogene Proteins c-bcl-2 0
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31M2U1DVID
Cyclooxygenase 2 EC 1.14.99.1
Phosphatidylinositol 3-Kinase EC 2.7.1.137
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3377-3383

Références

Biochim Biophys Acta. 2013 Apr;1835(2):164-9
pubmed: 23266512
Oral Oncol. 2009 Apr-May;45(4-5):440-6
pubmed: 18674958
J Cell Mol Med. 2005 Jan-Mar;9(1):59-71
pubmed: 15784165
Curr Drug Targets. 2017;18(14):1622-1640
pubmed: 27739372
Dev Cell. 2002 Nov;3(5):607-8
pubmed: 12431365
Biochim Biophys Acta. 1998 Dec 8;1436(1-2):127-50
pubmed: 9838078
Trends Pharmacol Sci. 2003 Feb;24(2):96-102
pubmed: 12559775
Clin Cancer Res. 2002 Jun;8(6):1957-63
pubmed: 12060641
Arch Oral Biol. 2017 Jan;73:1-6
pubmed: 27632413
PLoS One. 2008;3(12):e4070
pubmed: 19114998
Genes Dev. 2012 Jul 15;26(14):1573-86
pubmed: 22802530
PLoS One. 2014 Sep 05;9(9):e106571
pubmed: 25192188
J Mol Endocrinol. 2014 Oct;53(2):247-58
pubmed: 25125078
Metabolism. 2016 Feb;65(2):124-39
pubmed: 26773935
J Appl Physiol (1985). 2016 Oct 1;121(4):870-877
pubmed: 27539497
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Oncotarget. 2016 Dec 20;7(51):84999-85020
pubmed: 27829222
Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
pubmed: 16341064
Refuat Hapeh Vehashinayim (1993). 2015 Jul;32(3):55-63, 71
pubmed: 26548152
Mol Cell Biochem. 2017 Feb;426(1-2):27-45
pubmed: 27868170
Cell. 1997 Oct 17;91(2):231-41
pubmed: 9346240
BMC Cancer. 2006 Jan 30;6:27
pubmed: 16445867
Hum Pathol. 2015 Oct;46(10):1496-505
pubmed: 26256949
J Immunol Methods. 1986 May 22;89(2):271-7
pubmed: 3486233
Oncogene. 2008 Sep 18;27(41):5527-41
pubmed: 18794886
Curr Genomics. 2007 Aug;8(5):271-306
pubmed: 19384426
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9666-70
pubmed: 11493700
Biochem J. 2007 May 15;404(1):15-21
pubmed: 17302559
Neuroreport. 2018 Jun 13;29(9):718-722
pubmed: 29621055
Nature. 1997 Jul 17;388(6639):300-4
pubmed: 9230442
Oncogene. 1999 Dec 20;18(55):7908-16
pubmed: 10630643
Nature. 1995 Dec 21-28;378(6559):785-9
pubmed: 8524413
Mol Pharmacol. 2009 May;75(5):1231-9
pubmed: 19246337
Stem Cells Int. 2016;2016:2048731
pubmed: 27882058
J Biol Chem. 2004 Feb 13;279(7):5405-12
pubmed: 14645242

Auteurs

Andressa Duarte (A)

Department of Pathology and Forensic Medicine, Ribeirão Preto Medical School, University of São Paulo, Brazil.

Giórgia Gobbi Silveira (GG)

Department of Pathology and Forensic Medicine, Ribeirão Preto Medical School, University of São Paulo, Brazil.
Massachusetts General Hospital, Harvard Medical School, Boston, USA.

Danilo Figueiredo Soave (DF)

Department of Pathology and Forensic Medicine, Ribeirão Preto Medical School, University of São Paulo, Brazil.
Department of Stomatology (Oral Pathology), Dental School Federal University of Goiás Goiânia, Brazil.

João Paulo Oliveira Costa (JPO)

Department of Pathology and Forensic Medicine, Ribeirão Preto Medical School, University of São Paulo, Brazil.
Massachusetts General Hospital, Harvard Medical School, Boston, USA.

Alfredo Ribeiro Silva (AR)

Department of Pathology and Forensic Medicine, Ribeirão Preto Medical School, University of São Paulo, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH